TLX

Conviction 69HealthcareScan · Fri, Sep 25, 2026

Telix Pharmaceuticals Ltd (TLX) closed at $11.43 (+1.06%) on Sep 25, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 48, RS Rating 74, -10.9% from its 52-week high, +50.0% year to date. Sector: Healthcare · Biotechnology.

TLX$11.43+1.06%

ResistanceSupportVol 14Insider buy

Vol MA14 555.27K

Jun 29Jul 16Aug 4Aug 20Sep 9Sep 25

Telix Pharmaceuticals LtdBiotechnologywww.telixpharma.com ↗

Price11.43

Change+1.06%

Gap-0.31%

Rel volume—

Avg volume436.11K

Avg $ vol5.16M

SMA 2011.73

SMA 5011.32

SMA 2009.61

Price vs 50+0.97%

Price vs 200+18.95%

MA stackbullish

50/200 cross—

Supertrendup · 11.14

RSI (14)48

MACD hist-0.10

MACD crossbear · 4d

Stoch %K / %D29 / 25

ADX (14)16

+DI / −DI30 / 40

RSI divergence—

MACD divergence—

ATR %5.38%

ADR %3.00%

52w high12.83

52w low6.41

From 52w high-10.91%

Above 52w low+78.32%

New 52w highNo

SqueezeOff

Bollinger width17.75%

%B0.35

Donchian pos28.51%

Donchian high13.11

Donchian low10.76

AVWAP (52w high)11.87

vs AVWAP high-3.71%

AVWAP (52w low)10.06

vs AVWAP low+13.63%

OBV trendUp

Chaikin MF (20)-0.11

Today vs 20d—

Avg vol (14d)557.44K

Avg vol (20d)436.11K

Avg $ vol (20d)5.16M

Market cap3.87B

RS Rating74 / 99

RS 3m (vs SPY)+1.41%

RS 6m (vs SPY)+7.85%

RS line new highNo

Trend template8/8

Technical rank78.3

1 week-9.21%

1 month+2.70%

3 months+7.22%

6 months+27.42%

1 year+11.95%

YTD+50.00%

P/E—

P/B—

P/S—

P/FCF—

EPS—

Div yield—

ROE—

ROA—

Debt/Eq—

Current—

EV/EBITDA—

Gross margin—

Net margin—

Rev growth—

EPS growth—

Price target20.00

Target upside74.98%

Analyst ratingBuy

Institutional0.94%

Ent. value3.87B

Revenue—

Net income—

Gross profit—

Free cash flow—

IndustryBiotechnology

ExchangeNasdaq

Shares out339.38M

Employees1.18K

ListedWed, Nov 13, 2024

Free float273.62M

Float %80.8%

Short interest264.94K

Days to cover1.8d

Short volume83.3%

Squeeze score29 / 100

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeB

Conviction69 / 100

Pattern quality—

Tech rank78.3 / 100

Group rank50 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance12.95

Support10.78

Days since event—

Candle confirm—

Congress activity

Disclosed STOCK Act trades in TLX

All disclosures →

No recent disclosed trades by Congress in TLX. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in TLX · open-market 2 buys

Insider	Side	Shares	Value	Traded	Filed
Behrenbruch Christian MD & Group CEO · Ordinary Shares · 2026-04-29	Buy	33.44K	$497K	2026-04-29	2026-05-06
Behrenbruch Christian MD & Group CEO · Ordinary Shares · 2026-04-28	Buy	34.5K	$500K	2026-04-28	2026-05-06

SEC filings

EDGAR filings in TLX · 7 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.